东阿阿胶2024年净利润约为15.57亿元，较去年同期上涨35.29%

Dong-E-E-Jiao delivered strong financial performance in 2024 with significant growth.

1. Revenue reached ¥5.921 billion, up 25.57% year-on-year; net profit was ¥1.557 billion, rising 35.29% YoY, marking the fifth consecutive year of growth.

2. Net cash flow from operating activities was ¥2.171 billion, increasing 11.13% YoY, indicating healthy cash flow.

Product structure is dominated by the Ejiao series.

1. Ejiao and related products generated ¥5.544 billion in revenue, accounting for 93.64% of total revenue and representing the core business.

2. Other pharmaceuticals and health products contributed ¥236 million (3.98%), while donkey breeding and sales brought in ¥69 million (1.17%).

Brand marketing and dividend strategies proved effective.

1. The brand pursued rejuvenation through cross-platform collaborations, such as Bilibili's New Year's Eve Gala and Xiaohongshu's "Chinese-style Wellness Festival," and integrated into the popular drama "Joy of Life 2" to reinforce its positioning as a "national treasure of nourishment."

2. The dividend plan was generous: a cash dividend of ¥12.70 per 10 shares, totaling over ¥800 million, representing 99.7% of undistributed net profit.

Dong-E-E-Jiao's brand marketing strategy effectively drives brand renewal.

1. Efforts to rejuvenate the brand included collaborations with Bilibili's New Year's Eve Gala to boost exposure and Xiaohongshu's "Chinese-style Wellness Festival" to attract new consumer groups.

2. Creative integration into the hit drama "Joy of Life 2" continuously reinforced the value proposition of "Nourishing National Treasure, Dong-E-E-Jiao," enhancing brand influence.

Product R&D and brand portfolio diversification.

1. With "Dong-E-E-Jiao" as the core, supported by "Compound Ejiao Oral Liquid" and "Taohuaji," the brand extended into male health products like "Royal Hunting Ground 1619" and "Zhuangben," forming a synergistic "one superpower, multiple strengths" structure.

2. Financial growth reflects positive consumption trends, with revenue up 25.57% YoY, indicating potential in the traditional Chinese medicine market.

Market growth opportunities are evident, supported by consistent financial performance that boosts confidence.

1. Revenue of ¥5.921 billion (up 25.57% YoY) and net profit of ¥1.557 billion (up 35.29% YoY), with five years of consecutive growth, demonstrate stable industry demand.

2. Net operating cash inflow of ¥2.171 billion (up 11.13% YoY) indicates sufficient cash flow and minimal short-term risks.

Marketing collaborations and dividend models offer valuable insights.

1. Cross-platform partnerships, such as events with Bilibili and Xiaohongshu, provide case studies for managing promotional activities and enhancing positive impact; content marketing integration into dramas serves as a learning point for emerging collaboration methods.

2. The generous dividend plan (¥12.70 per 10 shares, totaling over ¥800 million) reflects corporate health and signals investment opportunities.

Production focus remains on the Ejiao series, with a stable supply chain.

1. Ejiao and related products generated ¥5.544 billion in revenue, accounting for 93.64%, highlighting concentrated demand in traditional Chinese medicine R&D and sales.

2. Donkey breeding contributed ¥69 million (1.17%), suggesting opportunities for supply chain integration.

Business opportunities lie in brand diversification and e-commerce collaborations.

1. The "one superpower, multiple strengths" brand structure, with core products like "Dong-E-E-Jiao" extending into male health items, offers insights for production expansion.

2. Marketing partnerships with platforms like Xiaohongshu for the "Chinese-style Wellness Festival" advance digital e-commerce, highlighting the importance of online channel development.

Industry trends show rejuvenation of consumer base, with digital collaboration becoming key.

1. Brand marketing shifts toward younger audiences through partnerships with Bilibili and Xiaohongshu, addressing client pain points like traditional brand aging.

2. Integration into hit dramas like "Joy of Life 2" offers content marketing solutions to boost brand influence.

Market potential is substantial, supported by financial data indicating demand.

1. Revenue growth of 25.57% YoY and net profit growth of 35.29% YoY, with five consecutive years of increase, reflect growth trends in the traditional Chinese medicine industry.

2. Increased operating cash inflow indicates industry stability, serving as a foundation for service solutions.

Effective platform collaboration cases highlight content marketing as a mainstream approach.

1. Partnerships with Bilibili's New Year's Eve Gala boosted platform exposure; collaboration with Xiaohongshu on the "Chinese-style Wellness Festival" strengthened merchant acquisition opportunities on social platforms.

2. Creative product placement in "Joy of Life 2" demonstrated the value of content platform partnerships, mitigating risks like user churn through diversified activities.

Platform demand and operational management insights.

1. Financial growth (revenue of ¥5.921 billion, up 25.57% YoY) reflects strong commercial demand for platforms, providing exemplary collaboration models.

2. Brand rejuvenation strategies highlight the need for platform merchant acquisition to focus on emerging consumer groups, with operational management attention to trend avoidance.

Industry developments focus on brand diversification and business model innovation.

1. The "one superpower, multiple strengths" brand structure—centered on "Dong-E-E-Jiao" with wings like "Compound Ejiao Oral Liquid" and "Taohuaji," extending into male health products—exemplifies business model synergy.

2. Five consecutive years of financial growth (revenue up 25.57% YoY, net profit up 35.29% YoY) indicate stability in the traditional Chinese medicine industry, with new challenges potentially involving supply chain optimization.

Policy implications for dividends and industry regulations.

1. The dividend plan of ¥12.70 per 10 shares, representing 99.7% of net profit, offers corporate governance policy insights, such as the impact of high payout ratios on shareholder returns.

2. Marketing collaborations with digital platforms suggest regulatory frameworks must adapt to content marketing trends, with business model analysis needed to study shifting consumption patterns.